Exelixis, Inc. $EXEL Shares Bought by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund raised its position in Exelixis, Inc. (NASDAQ:EXEL) by 72.8% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 171,474 shares of the biotechnology company’s stock after buying an additional 72,270 shares during the period. Illinois Municipal Retirement Fund owned about 0.06% of Exelixis worth $7,558,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of EXEL. Truist Financial Corp grew its position in shares of Exelixis by 1.1% during the 2nd quarter. Truist Financial Corp now owns 22,292 shares of the biotechnology company’s stock valued at $983,000 after acquiring an additional 250 shares during the period. Frank Rimerman Advisors LLC raised its holdings in Exelixis by 4.7% in the 1st quarter. Frank Rimerman Advisors LLC now owns 6,342 shares of the biotechnology company’s stock worth $234,000 after purchasing an additional 285 shares during the period. Rathbones Group PLC boosted its position in Exelixis by 5.3% during the first quarter. Rathbones Group PLC now owns 6,847 shares of the biotechnology company’s stock worth $253,000 after purchasing an additional 347 shares in the last quarter. Larson Financial Group LLC grew its holdings in Exelixis by 9.2% in the first quarter. Larson Financial Group LLC now owns 4,367 shares of the biotechnology company’s stock valued at $161,000 after purchasing an additional 367 shares during the period. Finally, Plato Investment Management Ltd grew its holdings in Exelixis by 6.5% in the second quarter. Plato Investment Management Ltd now owns 6,174 shares of the biotechnology company’s stock valued at $271,000 after purchasing an additional 377 shares during the period. 85.27% of the stock is owned by hedge funds and other institutional investors.

Exelixis Stock Up 3.8%

Shares of NASDAQ EXEL opened at $42.97 on Wednesday. The firm has a 50-day simple moving average of $39.16 and a 200-day simple moving average of $40.47. The stock has a market capitalization of $11.52 billion, a price-to-earnings ratio of 20.66, a price-to-earnings-growth ratio of 0.79 and a beta of 0.32. Exelixis, Inc. has a 52 week low of $31.90 and a 52 week high of $49.62.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.68 by $0.10. The company had revenue of $597.76 million during the quarter, compared to analysts’ expectations of $590.04 million. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. Exelixis’s revenue was up 10.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.47 EPS. Exelixis has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that Exelixis, Inc. will post 2.04 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. Leerink Partnrs raised Exelixis from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 21st. Royal Bank Of Canada reissued a “sector perform” rating and issued a $45.00 price target on shares of Exelixis in a report on Tuesday, October 21st. Wall Street Zen raised shares of Exelixis from a “buy” rating to a “strong-buy” rating in a report on Saturday. Barclays lifted their target price on shares of Exelixis from $40.00 to $41.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 5th. Finally, UBS Group upped their price target on shares of Exelixis from $35.00 to $40.00 and gave the stock a “neutral” rating in a research report on Thursday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and eleven have given a Hold rating to the company. Based on data from MarketBeat.com, Exelixis has an average rating of “Moderate Buy” and an average price target of $45.45.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.